In vitro antifungal activity of novel azole derivatives with a morpholine ring, UR-9746 and UR-9751, and comparison with fluconazole

Diagn Microbiol Infect Dis. 1997 Oct;29(2):103-6. doi: 10.1016/s0732-8893(97)00104-1.

Abstract

Thirty-three patient fungal isolates were studied by broth macrodilution methods for susceptibility to novel azole derivatives with a morpholine ring, UR-9746 and UR-9751, and fluconazole. MICs (micrograms/ml) ranged widely, but none had lower MICs for Candida albicans or Cryptococcus neoformans than UR-9751. Fluconazole and UR-9751 had the most activity versus other Candida species. Activity was demonstrated versus endemic fungal pathogens. Aspergillus species were generally resistant, although modest activity was seen. UR-9746 and UR-9751 are active in vitro, with a potency comparable to that of fluconazole.

Publication types

  • Comparative Study

MeSH terms

  • Antifungal Agents / pharmacology*
  • Antifungal Agents / therapeutic use
  • Culture Media
  • Fluconazole / pharmacology*
  • Fluconazole / therapeutic use
  • Fungi / drug effects*
  • Fungi / isolation & purification
  • Humans
  • Microbial Sensitivity Tests
  • Morpholines / pharmacology*
  • Morpholines / therapeutic use
  • Mycoses / drug therapy
  • Triazoles / pharmacology*
  • Triazoles / therapeutic use

Substances

  • Antifungal Agents
  • Culture Media
  • Morpholines
  • Triazoles
  • UR 9746
  • UR 9751
  • Fluconazole